Empagliflozin and Dapagliflozin Improve Endothelial Function in Mexican Patients with Type 2 Diabetes Mellitus: A Double-Blind Clinical Trial

被引:2
作者
Alejandri, Luis Ricardo Balleza [1 ]
Paez, Fernando Grover [1 ,2 ]
Campos, Erick Gonzalez [1 ]
Becerra, Carlos G. Ramos [1 ,2 ]
Munoz, Ernesto German Cardona [1 ,2 ]
Gonzalez, Sara Pascoe [1 ,2 ]
Zavala, Maria Guadalupe Ramos [1 ,2 ]
Roa, Africa Samantha Reynoso [1 ,2 ]
Rico, Daniel Osmar Suarez [1 ]
Ramirez, Alberto Beltran [1 ]
Galindo, Jesus Jonathan Garcia [1 ]
Mueller, David Cardona [1 ,2 ]
Ruiz, Claudia Yanette Galan [1 ,2 ]
机构
[1] Univ Guadalajara, Univ Hlth Sci Ctr, Dept Physiol, Guadalajara 44340, Mexico
[2] Univ Guadalajara, Univ Hlth Sci Ctr, Expt & Clin Therapeut Inst, Dept Physiol,Arterial Stiffness Lab, Guadalajara 44340, Mexico
关键词
type; 2; diabetes; empagliflozin; dapagliflozin; flow-mediated dilation; INHIBITION; ACTIVATION; FLOW;
D O I
10.3390/jcdd11060182
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim: To assess the acute effect of empagliflozin versus dapagliflozin administration on flow-mediated vasodilation in patients with type 2 diabetes mellitus. Design: A double-blind clinical trial, at the Experimental and Clinical Therapeutics Institute, University Health Sciences Center, at the Universidad de Guadalajara, in inpatients with T2D according to the 2023 ADA criteria. Methods: Thirty patients (15 males and 15 females), aged between 35 and 65 years, were included in this study, according to the 2023 ADA criteria. The eligible patients were randomly assigned to three groups: empagliflozin 25 mg once daily, dapagliflozin 10 mg once daily, or placebo once daily. Anthropometric parameters were taken using validated techniques. FMD was measured using a high-resolution semiautomatic ultrasound UNEX-EF 38G (UNEX Co., Ltd., Nagoya, Japan). Arterial tension was determined with the OMRON electronic digital sphygmomanometer (HEM 907 XL, Kyoto, Japan). Results: The group of patients who received empagliflozin had a significantly lower baseline flow-mediated dilation (FMD) compared to the group receiving dapagliflozin (p = 0.017); at the end of this study, the empagliflozin group achieved a comparable FMD to the dapagliflozin group (p = 0.88). Conclusion: After the treatment period, the empagliflozin and dapagliflozin groups achieved similar FMD, suggesting a class effect.
引用
收藏
页数:7
相关论文
共 24 条
[1]   FLOW-MEDIATED AND REFLEX CHANGES IN LARGE PERIPHERAL ARTERY TONE IN HUMANS [J].
ANDERSON, EA ;
MARK, AL .
CIRCULATION, 1989, 79 (01) :93-100
[2]   Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes-2019 [J].
Cefalu, William T. ;
Berg, Erika Gebel ;
Saraco, Mindy ;
Petersen, Matthew P. ;
Uelmen, Sacha ;
Robinson, Shamera .
DIABETES CARE, 2019, 42 :S34-S45
[3]   Dapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension [J].
Cefalu, William T. ;
Leiter, Lawrence A. ;
de Bruin, Tjerk W. A. ;
Gause-Nilsson, Ingrid ;
Sugg, Jennifer ;
Parikh, Shamik J. .
DIABETES CARE, 2015, 38 (07) :1218-1227
[4]   The worldwide epidemiology of type 2 diabetes mellitus-present and future perspectives [J].
Chen, Lei ;
Magliano, Dianna J. ;
Zimmet, Paul Z. .
NATURE REVIEWS ENDOCRINOLOGY, 2012, 8 (04) :228-236
[5]   Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery - A report of the International Brachial Artery Reactivity Task Force [J].
Corretti, MC ;
Anderson, TJ ;
Benjamin, EJ ;
Celermajer, D ;
Charbonneau, F ;
Creager, MA ;
Deanfield, J ;
Drexler, H ;
Gerhard-Herman, M ;
Herrington, D ;
Vallance, P ;
Vita, J ;
Vogel, R .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (02) :257-265
[6]   Hyperglycaemic impairment of PAR2-mediated vasodilation: Prevention by inhibition of aortic endothelial sodium-glucose-co-Transporter-2 and minimizing oxidative stress [J].
El-Daly, Mahmoud ;
Venu, Vivek Krishna Pulakazhi ;
Saifeddine, Mahmoud ;
Mihara, Koichiro ;
Kang, Sean ;
Fedak, Paul W. M. ;
Alston, Laurie A. ;
Hirota, Simon A. ;
Ding, Hong ;
Triggle, Chris R. ;
Hollenberg, Morley D. .
VASCULAR PHARMACOLOGY, 2018, 109 :56-71
[7]   Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2023 [J].
ElSayed, Nuha A. ;
Aleppo, Grazia ;
Aroda, Vanita R. ;
Bannuru, Raveendhara R. ;
Brown, Florence M. ;
Bruemmer, Dennis ;
Collins, Billy S. ;
Cusi, Kenneth ;
Hilliard, Marisa E. ;
Isaacs, Diana ;
Johnson, Eric L. ;
Kahan, Scott ;
Khunti, Kamlesh ;
Leon, Jose ;
Lyons, Sarah K. ;
Perry, Mary Lou ;
Prahalad, Priya ;
Pratley, Richard E. ;
Seley, Jane Jeffrie ;
Stanton, Robert C. ;
Gabbay, Robert A. .
DIABETES CARE, 2023, 46 :S49-S67
[8]   Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2023 [J].
ElSayed, Nuha A. ;
Aleppo, Grazia ;
Aroda, Vanita R. ;
Bannuru, Raveendhara R. ;
Brown, Florence M. ;
Bruemmer, Dennis ;
Collins, Billy S. ;
Das, Sandeep R. ;
Hilliard, Marisa E. ;
Isaacs, Diana ;
Johnson, Eric L. ;
Kahan, Scott ;
Khunti, Kamlesh ;
Kosiborod, Mikhail ;
Leon, Jose ;
Lyons, Sarah K. ;
Perry, Mary Lou ;
Prahalad, Priya ;
Pratley, Richard E. ;
Seley, Jane Jeffrie ;
Stanton, Robert C. ;
Gabbay, Robert A. .
DIABETES CARE, 2023, 46 :S158-S190
[9]  
Fowler M, 2008, Clin Diabetes, V26, P77, DOI DOI 10.2337/DIACLIN.26.2.77
[10]   Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation: A potential mechanism for inhibition of atherogenesis [J].
Gaspari, Tracey ;
Spizzo, Iressa ;
Liu, HongBin ;
Hu, Yunshan ;
Simpson, Richard W. ;
Widdop, Robert E. ;
Dear, Anthony E. .
DIABETES & VASCULAR DISEASE RESEARCH, 2018, 15 (01) :64-73